Cipla Limited
CIPLA
Rang in aandelen
#1814
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aandeelprijs
$14.61
Marktkapitalisatie
$11.80B
Verandering (1 dag)
-0.12%
Verandering (1 jaar)
-18.47%
Land
IN
Handel Cipla Limited (CIPLA)
Categorie
Healthcare
Operationele marge voor Cipla Limited (CIPLA)
Operationele marge op October 2026 TTM: 14.47%
Volgens de meest recente financiële rapporten en aandelenkoers van Cipla Limited is de huidige operationele marge (TTM) 14.47%. Eind 2024 had het bedrijf een operationele marge van 37.12%.
Geschiedenis van de operationele marge van Cipla Limited van 2004 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 14.47% | -62.43% |
| 2025 | 38.51% | 3.74% |
| 2024 | 37.12% | 7.41% |
| 2023 | 34.56% | -7.20% |
| 2022 | 37.24% | -3.17% |
| 2021 | 38.46% | -2.06% |
| 2020 | 39.27% | 1.87% |
| 2019 | 38.55% | -1.36% |
| 2018 | 39.08% | 1.27% |
| 2017 | 38.59% | -3.02% |
| 2016 | 39.79% | -1.66% |
| 2015 | 40.46% | 0.00% |
| 2014 | 40.46% | 77.30% |
| 2013 | 22.82% | 32.60% |
| 2012 | 17.21% | -100.50% |
| 2011 | -3,466.59% | -14,914.49% |
| 2010 | 23.40% | 24.87% |
| 2009 | 18.74% | -10.33% |
| 2008 | 20.90% | -10.99% |
| 2007 | 23.48% | -5.48% |
| 2006 | 24.84% | 3.76% |
| 2005 | 23.94% | 6.40% |
| 2004 | 22.50% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.42% |
IN
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.